{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:29:44Z","timestamp":1790357384260,"version":"4.1.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1097\/md.0000000000010122","type":"journal-article","created":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T17:08:53Z","timestamp":1520960933000},"page":"e0122","source":"Crossref","is-referenced-by-count":1,"title":["The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension"],"prefix":"10.1097","volume":"97","author":[{"given":"Zhi-Chun","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mang-Mang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Hua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jie","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210309","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"key":"R2-15-20210309","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1378\/chest.14-0793","article-title":"Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report","volume":"146","author":"Taichman","year":"2014","journal-title":"Chest"},{"key":"R3-15-20210309","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","article-title":"Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis","volume":"4","author":"Lajoie","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R4-15-20210309","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"key":"R5-15-20210309","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"R6-15-20210309","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"R7-15-20210309","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2165\/00002018-200528110-00001","article-title":"Risk management strategies in the post-marketing period: safety experience with the US and European bosentan surveillance programmes","volume":"28","author":"Segal","year":"2005","journal-title":"Drug Saf"},{"key":"R8-15-20210309","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacc.2012.03.025","article-title":"Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension","volume":"60","author":"Ben-Yehuda","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R9-15-20210309","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.amjcard.2012.06.040","article-title":"Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan","volume":"110","author":"Shapiro","year":"2012","journal-title":"Am J Cardiol"},{"key":"R11-15-20210309","doi-asserted-by":"crossref","first-page":"e003896","DOI":"10.1161\/JAHA.116.003896","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials","volume":"5","author":"Wei","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R12-15-20210309","doi-asserted-by":"crossref","first-page":"16218","DOI":"10.1038\/s41598-017-16349-7","article-title":"Incidence and risk of respiratory tract infection associated with specific drug therapy in pulmonary arterial hypertension: a systematic review","volume":"7","author":"Gu","year":"2017","journal-title":"Sci Rep"},{"key":"R13-15-20210309","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R14-15-20210309","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomized trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R15-15-20210309","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000010122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:59:37Z","timestamp":1620961177000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201803160-00015"}},"subtitle":["Protocol for a systemic review and network meta-analysis"],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000010122","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}